Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
Clinical trial NCT06314880 · UNKNOWN
Trial details
- NCT number
- NCT06314880
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-22
- Primary completion
- 2024-12-30
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.